When will current Series A startups raise their Series B?

When will current Series A startups raise their Series B?  Someone recently asked me this question, so I built a prediction model to help generate an answer. Keep reading as I discuss my process and give actual Series B predictions.  Where to begin?  I began by pulling together metrics that made sense for a company trying to raise a Series B. My thinking first went to a company's finances…

ChargePoint, Inc. to Become Public Company

Arc portfolio company ChargePoint announced that it will become a public company through a business combination with Switchback Energy Acquisition Corporation (NYSE:SBE), valued at $2.4 Billion. The official press release can be found here. ChargePoint, Inc. to Become Public Company, Advancing EV Charging Network’s Reach Across North America and Europe Business Combination with Switchback Energy…

PolyPid Ltd. Announces Closing of Initial Public Offering

PolyPid successfully completed its initial public offering on the NASDAQ, June 30th 2020. Arc Ventures first invested in the company in 2016. You can find more information about the investment here. PolyPid's original press release can be found on its website. PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option…

Facebook buys GIF website Giphy to integrate with Instagram

Giphy is a portfolio company of Arc Ventures' portfolio fund Betaworks. (from Reuters) - Facebook Inc is acquiring Giphy, a popular website for making and sharing animated images, or GIFs, Facebook said in a blog post on Friday. From Reuters: FILE PHOTO: A 3D printed Facebook logo is placed between small toy people figures in…

Ayala Pharmaceuticals Announces Closing of Initial Public Offering

Ayala is an Arc Ventures portfolio company since 2018 . The official press release can be found on the company's website. REHOVOT, Israel & WILMINGTON, Del., May 12, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and…